AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, com
Related Questions
Is there any indication of changes in cash flow, capital allocation, or share‑repurchase activity following the results?
Are there any changes in operating expenses, SG&A, or R&D spend that could affect profitability going forward?
How does Natera's Q2 performance stack up against major competitors such as Illumina, Roche, and Guardant Health?
How does the 63.4% gross margin compare to prior quarters and to peers in the cell‑free DNA space?
How might this results release influence analyst sentiment, target‑price revisions, and short‑term stock momentum?
What are the drivers behind the 32.3% product‑revenue increase and are they sustainable?
What are the key risks that could derail continued growth (e.g., competitive pressure, regulatory hurdles, reimbursement challenges)?
What is the expected impact of the 32.2% revenue growth on Natera's FY2025 earnings guidance?
Will the company raise its outlook for the full‑year 2025 based on this strong quarter?
Will the robust quarter trigger any notable insider buying or selling activity that could affect market perception?